

Supplementary Online Content


Norton C, Shaw MS, Rubnitz Z, et al. *KRAS* mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. *JAMA Netw Open*. 2025;8(1):e2453588. doi:10.1001/jamanetworkopen.2024.53588

eFigure. Time to Next Treatment and Overall Survival Across Common First-Line Treatments


This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Time to Next Treatment and Overall Survival Across Common First-Line Treatments


eFigure, A. Kaplan-Meier curve of time-to-next-treatment across first line treatment, with p-value from multivariable log-rank analysis



eFigure, B. Hazard ratios from multivariate Cox Proportional Hazard model for treatment progression, with FOLFIRINOX as reference



eFigure, C. Kaplan-Meier curve of overall survival across first line treatment, with p-value from multivariable log-rank analysis.



eFigure, D. Hazard ratios from a multivariate Cox Proportional Hazard model for death, with FOLFIRINOX as reference.

